Anna Bernsten

Doing our bit for the planet, starting with lunch. Good Made Easy. ☘️ Proud to be Irish 🌎 Proud to be a B Corp 🌱 Proud to be 100% plant-based

BioLamina is a Swedish biotechnology company with a global presence, offering cell culture matrices for primary cells. We offer an expansive portfolio of recombinant laminin proteins for a variety of applications, including the reliable expansion of pluripotent cell and differentiation and maintenance of specialized cell types. Our chemically defined and xeno-free laminin cell culture matrices allow you to imitate the natural cell-matrix interaction in vitro. Laminins are key components of the extracellular matrix. Through their interactions with specific receptors, laminins trigger the authentic cellular responses, pivotal for cell anchorage, survival, proliferation, migration, organization, and specialization, leading to improved cell functionality. BioLamina’s laminins are the only original full length, human, recombinant laminins on the market. Our high technology products contribute to our customer’s efficiency and scientific breakthroughs and enable them to start a new era in medical research. We are known and recognized for our premium products, competence, dedication, and service and position ourselves as being in the forefront of cell culturing. Our vision is to make BioLamina a leading brand within the field of cell culture and to help make cell therapy a reality. BioLamina is built on a scientific foundation with a legacy in matrix biology and solid experience in cell culture-based research. The company was started in 2009 and was co-founded by Dr. Karl Tryggvason and his son Dr. Kristian Tryggvason. Today the company has about 35 employees spanning from production, R&D, logistics, sales, and marketing. Our quality system complies with ISO 9001:2015 and both management and employees follow well-defined standard processes and agreements.

Our offering in developing and producing polymer-based products comprises everything from concept development, product design and process optimization, to high-volume production, post-processing, assembly and logistics. We partner and work closely with customers, and involvement at an early stage allows us to help develop successful, cost-effective products that are ready to manufacture. Nolato are working together with leading customers within medical technology, pharmaceuticals, consumer electronics, telecom, automotive and other selected industrial sectors. We have a long tradition of responsible business practice, and one of our Basic Principles is that efficient business operations must be combined with ethics, responsibility and environment awareness. These areas are consequently natural and integral aspects of our business operations. We are signatories to the UN Global Compact and report sustainability work in accordance with the GRI (Global Reporting Initiative). Nolato's shares are listed on Nasdaq Stockholm in the Large Cap segment, where they are included in the Industrials sector. Nolato has about 7,000 employees at units in Europe, Asia and North America.

DiaGenic is an innovative Norwegian diagnostic company that seeks to create value for patients, partners and investors by developing innovative and patient friendly in vitro diagnostic (IVD) products for early detection of diseases. The company’s proprietary concept implies that a disease evokes systemic responses in the blood unique for the disease, and which can be measured by using a blood sample. DiaGenic is a world leader in identifying gene expression signatures in blood and is focused on the development of IVD biomarker products in the field of Alzheimer’s disease. The company protects its technology through an extensive patent portfolio. DiaGenic is listed on the Oslo Stock Exchange. For more information please visit: www.diagenic.com

Doing our bit for the planet, starting with lunch. Good Made Easy. ☘️ Proud to be Irish 🌎 Proud to be a B Corp 🌱 Proud to be 100% plant-based

Ragn-Sells is a privately held corporate group, operating companies in four countries. Since 1966, weve been involved in waste management, environmental services and recycling. We collect, treat and recycle waste and residual products from businesses, organizations and households.

BioLamina is a Swedish biotechnology company with a global presence, offering cell culture matrices for primary cells. We offer an expansive portfolio of recombinant laminin proteins for a variety of applications, including the reliable expansion of pluripotent cell and differentiation and maintenance of specialized cell types. Our chemically defined and xeno-free laminin cell culture matrices allow you to imitate the natural cell-matrix interaction in vitro. Laminins are key components of the extracellular matrix. Through their interactions with specific receptors, laminins trigger the authentic cellular responses, pivotal for cell anchorage, survival, proliferation, migration, organization, and specialization, leading to improved cell functionality. BioLamina’s laminins are the only original full length, human, recombinant laminins on the market. Our high technology products contribute to our customer’s efficiency and scientific breakthroughs and enable them to start a new era in medical research. We are known and recognized for our premium products, competence, dedication, and service and position ourselves as being in the forefront of cell culturing. Our vision is to make BioLamina a leading brand within the field of cell culture and to help make cell therapy a reality. BioLamina is built on a scientific foundation with a legacy in matrix biology and solid experience in cell culture-based research. The company was started in 2009 and was co-founded by Dr. Karl Tryggvason and his son Dr. Kristian Tryggvason. Today the company has about 35 employees spanning from production, R&D, logistics, sales, and marketing. Our quality system complies with ISO 9001:2015 and both management and employees follow well-defined standard processes and agreements.

Probi® is a global company focused exclusively on researching, manufacturing, and delivering probiotics for supplements and functional food. We are experts at managing stable, live bacteria from R&D through every stage of the manufacturing process, and are dedicated to making the health-enhancing benefits of probiotics available to people everywhere. Our health concepts, formulations, and formats are supported by robust clinical documentation. Since our founding in 1991 at Sweden’s Lund University, Probi has expanded its operations to more than 40 markets. We hold more than 400 patents globally.